Citations

Mayo Clinic

Showing 10 of 108599 citations.

Left Ventricular Assist Device: Review of Antimicrobial Prophylaxis Strategies and Incidence of Infections at a Tertiary Care Center 12-Year Experience
Mendoza, Maria A. , Ranganath, Nischal , Garcia, Bismarck Bisono, Lahr, Brian D. , Stulak, John M., Shah, Aditya , Bisono, Bismarck , Mendoza, Maria Alejandra , Lahr, Brian , O'horo, John, Shah, Aditya S , Ranganath, Nischal , Bisono Garcia, Bismarck , Stevens, Ryan W. , O’Horo, John C.

Open Forum Infectious Diseases | September 8, 2023 | Volume: 10 | Issue: 9 | Pages: No page available

10.1093/ofid/ofad465 | PMID 37732167 Get It

Abstract Background Left ventricular assist devices (LVAD) have an associated infection rate of 13%–80% postimplant. An optimal strategy for surgical infection prophylaxis (SIP) at the time of implantation has not been well defined. We aimed to evaluate the different LVAD implantation antibiotic prophylaxis regimens as well as the incidence of LVAD infection at our institution. Methods We performed a single-center, retrospective study of patients who underwent LVAD implantation between February 2007 and June 2019. The primary outcome was the incidence of LVAD infection (LVADI), within 3 months and 1 year of placement, between patients who received expanded or narrow-spectrum regimens for SIP. We assessed outcomes using Kaplan-Meier, time-to-first event. We used a noninferiority analysis, which was established if the narrow-spectrum event rate was no more than 5% greater than the expanded-spectrum event rate. Results We included 399 patients, 305 (76.4%) patients received narrow-spectrum SIP, whereas the remaining 94 (23.6%) patients received the expanded-spectrum regimen. Statistical noninferiority of the narrow spectrum to the multiple drug regimen was demonstrated at both time points, and statistical superiority of the narrow-spectrum group across 12-month follow up was further evident (P = .037). Conclusions We report evidence supporting noninferiority, or even superiority, of the narrow-spectrum over expanded-spectrum antimicrobial prophylaxis strategy with respect to LVADI. These findings support data-driven antimicrobial prophylaxis strategies.
A human cadaveric model for venous air embolism tool development
Robinson, Nathaniel L. , Johnston, Matt, Abcejo, Arnoley S., Marcellino, Chris , Johnston, Matt

No container title available | September 8, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3320755/v1 | PMID 37720030 Get It

Abstract Purpose A human cadaveric model combining standard lung protective mechanical ventilation and modified cardiac bypass techniques was developed to allow investigation into automated modes of detection of venous air emboli (VAE) prior to in vivo human or animal investigations. Methods In this study, in order to create an artificial cardiopulmonary circuit in a cadaver that could mimic VAE physiology, the direction of flow was reversed from conventional cardiac bypass. Saline was circulated in isolation through the heart and lungs as opposed to the peripheral organs by placing the venous cannula into the aorta and the arterial cannula into the inferior vena cava with selective ligation of other vessels. Results Mechanical ventilation and this reversed cardiac bypass scheme allowed preliminary detection of VAE independently but not in concert in our current simulation scheme due to pulmonary edema in the cadaver. A limited dissection approach was used initially followed by a radical exposure of the great vessels, and both proved feasible in terms of air signal detection. We used electrical impendence as a preliminary tool to validate detection in this cadaveric model however we theorize that it would work for echocardiographic, intravenous ultrasound or other novel modalities as well. Conclusion A cadaveric model allows monitoring technology development with reduced use of animal and conventional human testing.
OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Youssef, George , Barboriak, Daniel P. , DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Barboriak, Daniel P , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, G, Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Preusser, Matthias , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii21-ii21

10.1093/neuonc/noad137.061 Get It

Abstract BACKGROUND The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. MATERIAL AND METHODS Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, the RANO working group developed updates to the RANO criteria (RANO 2.0). RESULTS Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment. CONCLUSION These criteria represent a work in progress that will hopefully improve the assessment of response in glioma trials. Future updates will incorporate novel developments, advanced imaging techniques, and endpoints as they become validated.
Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
Orenstein, Robert , Hecht, Gail , Tillotson, Glenn S. , Khanna, Sahil , Harvey, Adam

Open Forum Infectious Diseases | September 8, 2023 | Volume: 10 | Issue: 9 | Pages: No page available

10.1093/ofid/ofad456 | PMID 37691735 Get It

Commentary: French Military Neurosurgery: At Home and Abroad
Dagi, T. Forcht , Leavitt, Lydia, Dagi, T Forcht , Fox, W Christopher

Neurosurgery | September 8, 2023 | Volume: 94 | Issue: 2 | Pages: e28-e29

10.1227/neu.0000000000002675 | PMID 37681954 Get It

History and Future of Spinal Cord Stimulation
Ali, Rushna , Ali, Rushna , Schwalb, Jason M.

Neurosurgery | September 8, 2023 | Volume: 94 | Issue: 1 | Pages: 20-28

10.1227/neu.0000000000002654 | PMID 37681953 Get It

Spinal cord stimulation (SCS) is a surgical treatment for chronic neuropathic pain refractory to medical management. An SCS system comprised one or more leads implanted in the epidural space, typically connected to an implantable pulse generator. This review discusses the history, indications, surgical technique, technological advances, and future directions of SCS.
Detection and Mitigation of Neurovascular Uncoupling in Brain Gliomas
Agarwal, Shruti , Welker, Kirk M. , Black, David F. , Little, Jason T. , Passe, Theodore J. , Pillai, Jay J. , DeLone, David R. , Messina, Steven A. , Pillai, Jay J , Bettegowda, Chetan

Cancers | September 8, 2023 | Volume: 15 | Issue: 18 | Pages: 4473

10.3390/cancers15184473 | PMID 37760443 Get It

Functional magnetic resonance imaging (fMRI) with blood oxygen level-dependent (BOLD) technique is useful for preoperative mapping of brain functional networks in tumor patients, providing reliable in vivo detection of eloquent cortex to help reduce the risk of postsurgical morbidity. BOLD task-based fMRI (tb-fMRI) is the most often used noninvasive method that can reliably map cortical networks, including those associated with sensorimotor, language, and visual functions. BOLD resting-state fMRI (rs-fMRI) is emerging as a promising ancillary tool for visualization of diverse functional networks. Although fMRI is a powerful tool that can be used as an adjunct for brain tumor surgery planning, it has some constraints that should be taken into consideration for proper clinical interpretation. BOLD fMRI interpretation may be limited by neurovascular uncoupling (NVU) induced by brain tumors. Cerebrovascular reactivity (CVR) mapping obtained using breath-hold methods is an effective method for evaluating NVU potential.
Ethical Implications of Chatbot Utilization in Nephrology
Valencia, Oscar A. Garcia , Suppadungsuk, Supawadee , Miao, Jing , Tangpanithandee, Supawit , Craici, Iasmina , Cheungpasitporn, Wisit , Garcia-Valencia, Oscar , Miao, Jing , Tangpanithandee, Supawit , Craici, Iasmina M, Cheungpasitporn, Wisit , Suppadungsuk, Supawadee , Thongprayoon, Charat

Journal of Personalized Medicine | September 8, 2023 | Volume: 13 | Issue: 9 | Pages: 1363

10.3390/jpm13091363 | PMID 37763131 Get It

This comprehensive critical review critically examines the ethical implications associated with integrating chatbots into nephrology, aiming to identify concerns, propose policies, and offer potential solutions. Acknowledging the transformative potential of chatbots in healthcare, responsible implementation guided by ethical considerations is of the utmost importance. The review underscores the significance of establishing robust guidelines for data collection, storage, and sharing to safeguard privacy and ensure data security. Future research should prioritize defining appropriate levels of data access, exploring anonymization techniques, and implementing encryption methods. Transparent data usage practices and obtaining informed consent are fundamental ethical considerations. Effective security measures, including encryption technologies and secure data transmission protocols, are indispensable for maintaining the confidentiality and integrity of patient data. To address potential biases and discrimination, the review suggests regular algorithm reviews, diversity strategies, and ongoing monitoring. Enhancing the clarity of chatbot capabilities, developing user-friendly interfaces, and establishing explicit consent procedures are essential for informed consent. Striking a balance between automation and human intervention is vital to preserve the doctor–patient relationship. Cultural sensitivity and multilingual support should be considered through chatbot training. To ensure ethical chatbot utilization in nephrology, it is imperative to prioritize the development of comprehensive ethical frameworks encompassing data handling, security, bias mitigation, informed consent, and collaboration. Continuous research and innovation in this field are crucial for maximizing the potential of chatbot technology and ultimately improving patient outcomes.
Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms
Gaulin, Charles , Craig, Fiona E. , Ensign, Shannon P. Fortin , Robetorye, Ryan S. , Kelemen, Katalin, Khera, Nandita , Leis, José F., Palmer, Jeanne , Craig, Fiona, Fortin Ensign, Shannon, Robetorye, Ryan, Leis, Jose, Ensign, Shannon P. Fortin , Gibson, Sarah E. , Tsang, Mazie , Rosenthal, Allison , Muñoz, Javier , Hilal, Talal

Leukemia & Lymphoma | September 8, 2023 | Volume: 64 | Issue: 14 | Pages: 2347-2350

10.1080/10428194.2023.2255707 | PMID 37680001 Get It

Electronic Patient-Reported Outcome Data Collection Systems in Oncology Clinical Trials: A Survey of Clinical Research Professionals (an Alliance Study)
Cho, Youmin , Zahrieh, David , Chow, Selina , Williams, David A. , Arnault, Denise Saint , Jiang, Yun , Lavoie Smith, Ellen M , Zahrieh, David , Williams, David A , Saint Arnault, Denise , Jiang, Yun

JCO Clinical Cancer Informatics | September 7, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/cci.23.00007 | PMID 37677111 Get It

PURPOSE To describe clinical research professionals (CRPs)’ experiences with electronic patient-reported outcome (ePRO) data collection systems in oncology clinical trials and identify correlates of CRPs' attitude toward technology. METHODS An online survey was conducted among 210 CRPs from 125 National Cancer Institute–funded research sites. Measures included CRPs' demographic characteristics, working years, employment locations, and previous experiences with various types of ePROs. Their attitude toward technology was measured by the Technology Attitude Scale-Adapted. The Wilcoxon signed-rank test was used to compare two subdomains of attitude (perceived usefulness [PU] and perceived ease of use [PEU]). Multiple linear regression was used to explore correlates of (1) overall attitude, (2) PU, and (3) PEU. The significance level was 5%. RESULTS Participants' median age was 41 years (range, 21-67). Most were female (90%) and White (82%). More than half of the participants had previous experiences with web-based ePROs using patients' own devices (72%) or site-/sponsor-provided on-site devices (eg, kiosks or tablets; 64%). CRPs who were 60 years or older (β = −0.32, P < .05) or worked for 10-20 years (β = −0.11, P < .05) had relatively negative attitudes, controlling for other factors. Previous experiences with more ePRO types were associated with more positive attitudes (β = 0.08, P = .02). Similar correlates were found with PU but not with PEU. CONCLUSION This study revealed that CRPs had various experiences with ePRO systems and attitudes toward technology. Age, working years, and previous experiences with ePROs were correlates of overall attitude toward technology and PU. These findings suggest necessary targeted training to facilitate ePRO use in oncology clinical trials by improving CRPs' awareness and attitude toward technology.